Related Experiment Video
Updated: Feb 14, 2026

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
Preclinical study of a Kv11.1 potassium channel activator as antineoplastic approach for breast cancer
Daniela F Fukushiro-Lopes1, Alexandra D Hegel1, Vidhya Rao1,2
1Department of Molecular Pharmacology and Therapeutics, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA.
Abstract:
Potassium ion (K+) channels have been recently found to play a critical role in cancer biology. Despite that pharmacologic manipulation of ion channels is recognized as an important therapeutic approach, very little is known about the effects of targeting of K+ channels in cancer. In this study, we demonstrate that use of the Kv11.1 K+ channel activator NS1643 inhibits tumor growth in an in vivo model of breast cancer. Tumors exposed to NS1643 had reduced levels of proliferation markers, high expression levels of senescence markers, increased production of ROS and DNA damage compared to tumors of untreated mice. Importantly, mice treated with NS1643 did not exhibit significant cardiac dysfunction. In conclusion, pharmacological stimulation of Kv11.1 activity produced arrested TNBC-derived tumor growth by generating DNA damage and senescence without significant side effects. We propose that use of Kv11.1 channels activators could be considered as a possible pharmacological strategy against breast tumors.
Insights
Targeting potassium channels with NS1643 halts breast tumor growth. This approach induces DNA damage and senescence in cancer cells without causing cardiac side effects, offering a potential new therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Potassium ion (K+) channels are increasingly recognized for their role in cancer biology.
- Pharmacological targeting of ion channels is a promising therapeutic strategy, but K+ channel roles in cancer remain underexplored.
Purpose of the Study:
- To investigate the effects of targeting Kv11.1 potassium channels in an in vivo breast cancer model.
- To evaluate the efficacy and safety of the Kv11.1 activator NS1643 in inhibiting tumor growth.
Main Methods:
- Utilized an in vivo model of breast cancer treated with the Kv11.1 activator NS1643.
- Assessed tumor growth, proliferation markers, senescence markers, reactive oxygen species (ROS) production, and DNA damage.
- Monitored for cardiac dysfunction in treated mice.
Main Results:
- NS1643 treatment significantly inhibited tumor growth in the breast cancer model.
- NS1643-treated tumors showed reduced proliferation, increased senescence markers, elevated ROS, and DNA damage.
- No significant cardiac dysfunction was observed in mice treated with NS1643.
Conclusions:
- Pharmacological stimulation of Kv11.1 channels with NS1643 effectively arrested tumor growth in triple-negative breast cancer (TNBC) models.
- The mechanism involves inducing DNA damage and senescence in cancer cells.
- Kv11.1 channel activators represent a potential therapeutic strategy for breast tumors with minimal side effects.
More Related Videos
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Regulation of Sodium and Potassium
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
Ion Channels
Ion channels are specialized integral membrane proteins on the plasma membrane that allow...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Roles of Electrolytes: Sodium and Potassium

